Zura Bio (ZURA) Liabilities and Shareholders Equity (2021 - 2026)

Zura Bio's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $228.6 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 32.55% year-over-year to $228.6 million in Q1 2026; TTM through Mar 2026 was $644.3 million, a 11.81% decrease from a year earlier, with the FY2025 full-year figure at $113.9 million, down 36.53% from the prior year.
• Liabilities and Shareholders Equity climbed to $228.6 million in Q1 2026 per ZURA's latest filing, from $113.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $228.6 million in Q1 2026 and bottomed at $5.3 million in Q4 2022.
• The 5-year median for Liabilities and Shareholders Equity is $140.3 million (2022), against an average of $132.6 million.
• Across the five-year window, Liabilities and Shareholders Equity tumbled 96.26% in 2022 and soared 1816.44% in 2023, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $5.3 million in 2022, then surged by 1816.44% to $100.8 million in 2023, then jumped by 78.03% to $179.5 million in 2024, then sank by 36.53% to $113.9 million in 2025, then soared by 100.65% to $228.6 million in 2026.
• Per Business Quant, the three latest ZURA Liabilities and Shareholders Equity figures stand at $228.6 million (Q1 2026), $113.9 million (Q4 2025), and $143.9 million (Q3 2025).